Phase I trials in oncology: a new era has started. (Q54312153)

27 May 2018

editorial

0 references

title

Phase I trials in oncology: a new era has started. (English)

1 reference

27 May 2018

main subject

phase I clinical trial

0 references

author name string

S Postel-Vinay

series ordinal

1

1 reference

27 May 2018

J-C Soria

series ordinal

2

1 reference

27 May 2018

publication date

30 October 2014

1 reference

27 May 2018

published in

Annals of Oncology

1 reference

27 May 2018

volume

26

1 reference

27 May 2018

issue

1

1 reference

27 May 2018

page(s)

7-9

1 reference

27 May 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Modifying phase I methodology to facilitate enrolment of molecularly selected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU513

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU513

1 reference

27 May 2018

1 reference

27 May 2018